Allogene Therapeutics Inc (ALLO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.69 (-2.31%), Market cap $0.79B, 52-week low–high $0.95 ~ $3.06.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70
Financial statements, price targets, institutional (13F) holdings and related news for Allogene Therapeutics Inc are updated in real time on BlackAll Trade.
Allogene Therapeutics Inc trades at $1.69 (-2.31%). Real-time quotes and charts are available on BlackAll Trade.
Allogene Therapeutics Inc has a market cap of about $0.79B.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases